Open Access“I Think It’s Been Met With a Shrug:” Oncologists’ Views Toward and Experiences With Right-to-Try
Author(s) -
Cambray Smith,
Jeremiah Stout,
Alex A. Adjei,
Jan C. Buckner,
Mark Wentworth,
Jon C. Tilburt,
Zubin Master
Publication year - 2020
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djaa137
Subject(s) - legislation , confusion , compassionate use , obligation , medicine , expanded access , food and drug administration , alternative medicine , clinical trial , family medicine , psychology , political science , pharmacology , oncology , law , pathology , psychoanalysis
The federal Right-to-Try (RTT) Act created an alternate regulatory pathway for preapproval access to investigational drugs. A few studies have examined the experiences of physicians with the Food and Drug Administration's Expanded Access Programs, but to our knowledge, no study has yet to examine their attitudes and experiences toward RTT.